HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

October 1, 2016

Study Completion Date

January 24, 2017

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Hepatic arterial infusion

A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially

PROCEDURE

Transarterial chemoembolization

Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.

DRUG

Folfox Protocol

oxaliplatin,leucovorin and 5-FU

DRUG

TACE Drug Protocol

lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)

Trial Locations (1)

510060

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03048123 - HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | Biotech Hunter | Biotech Hunter